Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment - Stangier, J; Stahle, H; Rathgen, K (J Clin Pharmacol, 2008)
et al.